No Data
No Data
When Can We Expect A Profit From Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)?
Mirum Pharmaceuticals Director Buys Shares Worth $4,301
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Insiders At Mirum Pharmaceuticals Sold US$623k In Stock, Alluding To Potential Weakness
Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern